PMVP - NASDAQ
PMV Pharmaceuticals, Inc.
$1.19
+1.7%PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
At a Glance
Live SnapshotPMV Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
PMV Pharmaceuticals, Inc. Balance Sheet
PMVP • NASDAQ
| PMV Pharmaceuticals, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
38M | 40.9M | 37.7M | 108.3M | 172.5M | 361.4M | 73.3M | 30.3M | |
75M | 128.6M | 165.4M | 132.8M | 124.7M | 0.0 | 28.2M | 31.6M | |
112.9M | 169.5M | 203.1M | 241.1M | 297.2M | 361.4M | 101.5M | 61.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 3.3M | 0.0 | 607K | 332K | |
2.3M | 6.2M | 4.4M | 6M | 822K | 3.3M | 0.0 | 0.0 | |
115.2M | 175.7M | 207.4M | 247M | 301.3M | 364.8M | 102.1M | 62.2M | |
NON-CURRENT ASSETS | ||||||||
1M | 1.6M | 19M | 20.5M | 13.2M | 569K | 739K | 1M | |
0.0 | 13.8M | 25.5M | 2.5M | 16.9M | 0.0 | 0.0 | 0.0 | |
297K | 235K | 190K | 313K | 221K | 201K | 201K | 201K | |
1.3M | 15.6M | 44.7M | 23.3M | 30.3M | 770K | 940K | 1.2M | |
116.6M | 191.3M | 252.2M | 270.3M | 331.6M | 365.5M | 103M | 63.5M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
3.2M | 6.6M | 3.2M | 3M | 3.2M | 1.6M | 2.8M | 1M | |
3.2M | 6.6M | 3.2M | 3M | 3.2M | 1.6M | 2.8M | 1M | |
0.0 | 2.4M | 5.4M | 7.3M | 4.8M | 4.8M | 1.7M | 1.3M | |
403K | 352K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 852K | 528K | 403K | 0.0 | 0.0 | 0.0 | |
7.9M | 5M | 4.5M | 0.0 | 3.8M | 0.0 | 0.0 | 0.0 | |
11.4M | 14.4M | 14M | 10.8M | 12.2M | 6.4M | 4.5M | 2.3M | |
NON-CURRENT LIABILITIES | ||||||||
435K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 169M | 107.3M | |
435K | 838K | 12.4M | 13.4M | 10.8M | 0.0 | 169M | 107.3M | |
0.0 | 838K | 13.3M | 14M | 11.2M | 0.0 | 0.0 | 0.0 | |
11.9M | 15.2M | 26.5M | 24.3M | 23M | 6.4M | 173.5M | 109.6M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 168.9K | 107.2M | |
551.1M | 0.0 | 535.5M | 487.5M | 476.4M | 469M | 5M | 4M | |
-446.5M | -368.7M | -310M | -241M | -167.7M | -109.9M | -75.4M | -50.1M | |
84K | 139K | 224K | -445K | -78K | 0.0 | -3K | -13K | |
0.0 | 544.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
104.7M | 176.1M | 225.7M | 246M | 308.6M | 359.1M | -70.5M | -46.1M | |
104.7M | 176.1M | 225.7M | 246M | 308.6M | 359.1M | -70.5M | -46.1M | |
SUMMARY | ||||||||
116.6M | 191.3M | 252.2M | 270.3M | 331.6M | 365.5M | 103M | 63.5M | |
75M | 142.4M | 190.9M | 135.3M | 141.6M | 0.0 | 28.2M | 31.6M | |
838K | 1.2M | 13.3M | 14M | 11.2M | 0.0 | 168.9M | 107.2M | |
-37.1M | -39.7M | -24.4M | -94.3M | -161.3M | -361.4M | 95.7M | 76.9M | |
52,990,864 | 52,990,864 | 52,990,864 | 52,990,864 | 52,990,864 | 52,990,864 | 52,990,864 | 52,990,864 |
SEC Filings
PMVP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 06, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 10, 2025 | September 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 |
Related Guides
Continue your PMVP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.